Dr Lindsay McGrath recently had the privilege of contributing to a groundbreaking paper in collaboration with the esteemed team at QUT.
Published in The Ocular Surface journal, this paper unveils the promising results of a phase-2 multicentre trial investigating a new type of eye ointment which contains selenium for patients with severe dry eye related to meibomian gland dysfunction. Patients showed statistically significant improvement in symptoms with minimal side effects.
But the journey doesn’t end here! With the ointment’s path to FDA approval underway and further trials on the horizon, we hope that eventually it will be available in Australia for our dry eye patients.
As advocates for the best in eye care, we’re elated to be part of this transformative journey.
Read more about the study: 10.1016/j.jtos.2023.07.002